Recent News

• 06.09.2025 - Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025
• 06.04.2025 - Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
• 05.29.2025 - Sagimet Biosciences Virtual KOL Event - Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• 05.22.2025 - Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025
• 05.20.2025 - Denifanstat improved multiple qFibrosis-based collagen features linked to major adverse liver outcomes in patients with metabolic dysfunction-associated steatohepatitis patients and high polygenic risk
• 05.20.2025 - Assessment of metabolic dysfunction-associated steatohepatitis resolution index and component biomarkers in prediction of histology response to denifanstat in the FASCINATE-2 trial
• 05.20.2025 - Denifanstat-mediated reduction of plasma glycine- and taurine-conjugated bile acids correlates with histological improvements in denifanstat-treated metabolic dysfunction-associated steatohepatitis patients in Phase 2b FASCINATE-2 study
• 05.08.2025 - Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
• 04.23.2025 - Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025

Recent Filings

• 06.04.2025 - 8-K Current report
• 06.04.2025 - EX-99.1 EX-99.1
• 05.20.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.08.2025 - EX-99.1 EX-99.1
• 05.08.2025 - 8-K Current report
• 05.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.30.2025 - 8-K Current report
• 04.30.2025 - ARS Annual Report to Security Holders